Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers
DURHAM, N.C. The addition of a chemotherapeutic drug for leukemia to a standard regimen of two other chemotherapy drugs appears to enhance the response of certain ovarian cancers to treatment, according to a pre-clinical study led by researchers in the Duke Comprehensive Cancer Center.
Wonder drug Dasatinib gives hopes to leukemia patients
The company Bristol-Myers Squibb Co at Boston told the press that the drug Dasatinib
has led to reduction in the number of patients with Chronic myeloid leukemia (CML).//
This drug is very effective in the decreasing the leukemia cells from the bone marrow than the previously used drug Gleevec...
Chemo Combo Shows Promise Against Ovarian Cancer
...NDAY, April 19 (HealthDay News) -- Adding the drug dasatinib
to a standard, two-drug chemotherapy regimen for t...termined that the combination of the leukemia drug dasatinib
(Sprycel) made carboplatin and paclitaxel more eff... able to direct the use of a targeted therapy like dasatinib
based on gene expression pathways in select ovaria...
New Cancer Drug Tied to Heart Problems
...ors, which target key molecular pathways thought to encourage tumor growth. Other drugs in this family include imatinib, better known as Gleevec, and dasatinib
In the study, which is published in the Dec. 15 issue of The Lancet , Chen's team looked at 75 patients with metastatic, gastrointestin...
Early Phase II results show bosutinib safe, effective for CML
...ients who had also become resistant to second-line treatments nilotinib and dasatinib
derived some benefit from taking the new drug. Out of eight such patients, ...oups to proteins or small molecules. Bosutinib, like imatinib (Gleevec(r)), dasatinib
(Sprycel(r)) and nilotinib (Tasigna(r)), is a tyrosine kinase inhibitor.
Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia
...alled blasts that crowd out red blood cells and platelets.
Nilotinib and dasatinib
target a greater variety of genetic variations leading to CML than does ima..., developed, designed and conducted clinical trials that led to approval of dasatinib
by the FDA in June 2007 for the same group of patients. Talpaz is now at th...
Scientists discover new role for miRNA in leukemia
...ght represent a potentially new therapeutic strategy for CML patients who do not benefit from effective targeted agents such as imatinib (Gleevec) and dasatinib
(Sprycel), says principal investigator Danilo Perrotti, assistant professor of molecular virology, immunology and medical genetics and a researcher wi...
SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition
...CR-ABL inhibited by SGX393 is the T315I
mutation, which is also resistant to the two second-generation BCR-ABL
inhibitors, nilotinib (Tasigna (R)) and dasatinib
(Sprycel (R)). In
addition, SGX is engaged in a strategic collaboration with Novartis that
aims to discover and develop next generation BCR-ABL inhibi...
Can cancer drugs combine forces?
...inib, individuals are treated with a drug known as dasatinib
(SPRYCEL), which targets BCR-ABL in a different wa...nts whose cancer had returned after treatment with dasatinib
responded to retreatment with imatinib. Analysis o...tation that rendered the protein resistant to both dasatinib
and imatinib or had two mutations, one rendering t...
New Strategy for the Treatment of CML
...t and colleagues examined the effects of combining dasatinib
with PD184352, another clinically relevant small m...und that combining extremely low concentrations of dasatinib
with PD184352 resulted in a dramatic increase in a...of newer, more effective kinase inhibitors such as dasatinib
for diseases such as CML is a clear priority, resi...